An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

The Safety Analysis set included all randomized participants who received at least 1 dose of study intervention. Arm groups were based upon the actual treatment received for the purpose of safety analysis.

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were defined as AEs occurring at or after the first dose date and time, through study termination, or existing prior to the time of and worsening after the time of the first dose of investigational product. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

The Full Analysis Set included all enrolled participants in Part 2 who received at least 1 dose of study intervention.

The PK Analysis set included all randomized participants who received at least 1 dose of study intervention and had at least 1 on-study PK measurement.

The PK Analysis set included all randomized participants who received at least 1 dose of study intervention and had at least 1 on-study PK measurement.

The PK Analysis set included all randomized participants who received at least 1 dose of study intervention and had at least 1 on-study PK measurement.

The PK Analysis set included all randomized participants who received at least 1 dose of study intervention and had at least 1 on-study PK measurement.

NAS was the sum of the scores of steatosis, inflammation, and ballooning. NAS score ranges from of 0 to 8, with higher scores indicating worse disease severity.

Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH Clinical Research Network (CRN) fibrosis score.

NASH CRN Fibrosis is staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

The Histology Biopsy Analysis Set included all enrolled participants who received at least 1 dose of study intervention and who had both baseline (screening or eligible historical) and post-baseline biopsies.

Number of participants with anti-pegozafermin antibodies (ADA) with status as ADA positive has been reported.

The Safety Analysis set included all randomized participants who received at least 1 dose of study intervention. Arm groups were based upon the actual treatment received for the purpose of safety analysis.

Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM).

The analysis set included all randomized participants who received at least 1 dose of study intervention and who had measurable post-baseline PD data in Parts 1 and 2. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

LS Mean was calculated using MMRM.

The analysis set included all randomized participants who received at least 1 dose of study intervention and who had measurable post-baseline PD data in Parts 1 and 2. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

LS Mean was calculated using MMRM. HOMA-IR value was calculated by multiplying fasting Glucose (mg/dL) with fasting Insulin (uIU/ml) and then dividing by 405.

The analysis set included all randomized participants who received at least 1 dose of investigational product and who had measurable post-baseline PD data in Part 1. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

LS Mean was calculated using MMRM.

The analysis set included all randomized participants who received at least 1 dose of investigational product and who had measurable post-baseline PD data in Part 1. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

LS Mean was calculated using MMRM.

The analysis set included all randomized participants who received at least 1 dose of study intervention and who had measurable post-baseline PD data in Part 1. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

LS Mean was calculated using MMRM. Adipo-IR was derived from fasting insulin and free fatty acid.

The analysis set included all randomized participants who received at least 1 dose of study intervention and who had measurable post-baseline PD data in Part 1. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

LS Mean was calculated using MMRM.

The analysis set included all randomized participants who received at least 1 dose of study intervention and who had measurable post-baseline PD data in Parts 1 and 2. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

Fibrosis improvement was defined as ≥1-stage decrease in NASH CRN fibrosis score.

Worsening of NASH was defined as increase ≥1 point in NAS for ballooning or inflammation.

NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

The Histology Biopsy Analysis Set included all enrolled participants who received at least 1 dose of study intervention and who had both baseline (screening or eligible historical) and post-baseline biopsies.

Resolution of NASH included the total absence of ballooning (score=0) and absent or mild inflammation (score 0 to 1).

Worsening of fibrosis was defined as progression of fibrosis ≥1 stage in NASH CRN fibrosis score.

NASH CRN Fibrosis was staged on a 0-4 scale: 0 (none); 1 (perisinusoidal or periportal fibrosis); 2 (perisinusoidal and portal/periportal fibrosis); 3 (bridging fibrosis); 4 (cirrhosis).

The Histology Biopsy Analysis Set included all enrolled participants who received at least 1 dose of study intervention and who had both baseline (screening or eligible historical) and post-baseline biopsies.